Larry Rubinstein
National Cancer Institute · 463 works · 67,243 citations · h-index 70
Top works
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
- An Information-Intensive Approach to the Molecular Pharmacology of Cancer
- Modern thirty-day operative mortality for surgical resections in lung cancer
- Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines
- Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
- Individual patient data analysis to assess modifications to the RECIST criteria
- Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
- Recommendations for the assessment of progression in randomised cancer treatment trials
- Lessons learned from independent central review
- Validation of novel imaging methodologies for use as cancer clinical trial end-points
- Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies.
- Accelerated Titration Designs for Phase I Clinical Trials in Oncology
- Neural Computing in Cancer Drug Development: Predicting Mechanism of Action
- Cancer recurrence after resection: T1 N0 non-small cell lung cancer
- Likelihood Calculations for Matched Case-Control Studies and Survival Studies with Tied Death Times
- A comparison of two phase I trial designs
- New guidelines to evaluate the response to treatment in solid tumors
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?